WHO ICTRP trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to…
JPRN-jRCT2080221194 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221194 |
|---|---|
| Public title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain. |
| Scientific title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain. |
| Primary sponsor | Taiho Pharmaceutical Co., Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Cancer-related pain (breakthrough pain) |
| Interventions | investigational material(s) Generic name etc : OVF INN of investigational material : fentanyl Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Investigational material : The first dose is started from the… |
| Registration date | Oct 8, 2010 |
| Secondary IDs | JapicCTI-101231 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: